# MRNA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/MRNA) · [Earnings tab](https://www.lopjlb.com/stock/MRNA?tab=earnings)

Updated: 2026-08-01T05:07:53

Quarters analyzed: 8

## Cross-quarter narrative

Across the earnings calls, Moderna's tone and guidance have fluctuated, reflecting changes in demand, regulatory approvals, and pipeline progress. Initially, the company faced challenges with weak EU demand, US competitive pressures, and potential revenue deferrals. However, subsequent calls highlighted cost cuts, pipeline progress, and regulatory approvals, including those for mNEXSPIKE and mRESVIA. Despite these positives, concerns around declining COVID vaccination rates, regulatory uncertainty, and market competition have persisted. The company has also navigated delays and setbacks, such as the discontinuation of the CMV congenital vaccine program and the low case accrual in the Norovirus trial. Overall, Moderna's narrative has been marked by a mix of progress and challenges, with a focus on cost discipline, pipeline investment, and strategic partnerships.

## Latest CallCard · Q1

Moderna Q1 2026: $400M revenue (+$300M YoY), net loss $1.3B GAAP ($0.5B ex-litigation), cash $7.5B; reiterated up to 10% FY revenue growth; EU approvals for mNEXSPIKE and flu+COVID combo; flu PDUFA Aug 5; Intismeran Phase III in Stage 1 NSCLC monotherapy initiated; norovirus Phase III enrolled; $950

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Moderna Q1 2026: $400M revenue (+$300M YoY), net loss $1.3B GAAP ($0.5B ex-litigation), cash $7.5B; reiterated up to 10% FY revenue growth; EU approvals for mNEXSPIKE and flu+COVID combo; flu PDUFA Aug 5; Intismeran Phase III in Stage 1 NSCLC monotherapy initiated; norovirus Phase III enrolled; $950
- **2025 Q4:** Moderna posted $1.9B revenue, cut operating expenses, but faces regulatory uncertainty for its flu vaccine while targeting 10% revenue growth in 2026 driven by mNEXSPIKE and new partnerships.
- **2025 Q3:** Moderna reports $1B Q3 revenue, $200M loss, strong cost cuts and vaccine approvals while navigating declining US COVID demand and mixed trial outcomes.
- **2025 Q2:** Moderna Q2 2025: $2.1B revenue, $0.8B loss, 3 FDA approvals (mNEXSPIKE, mRESVIA, pediatric Spikevax), positive flu Phase III, cost cuts accelerated ($400M more), 10% headcount reduction, 2025 revenue guidance lowered to $1.5-2.2B on UK timing shift.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Manageme
- **2025 Q1:** Moderna Q1 2025: $108M revenue, $1B loss, $8.4B cash; 19% YoY cost reduction; 2025 guidance maintained ($1.5-2.5B revenue); 2026/2027 cost targets lowered; pipeline updates: COVID/RSV PDUFAs near, Flu+COVID delayed to 2026, CMV Phase III readout H2, norovirus enrollment ongoing, oncology checkpoint 
- **2024 Q4:** Moderna posted $3.2B Q4 revenue, $9.5B cash, cut $2.6B costs, launched mRESVIA, filed three respiratory BLAs and sees guidance uncertainty around vaccination rates and product approvals.
- **2024 Q3:** Moderna posted $1.9B Q3 revenue, reaffirmed $3‑$3.5B 2024 sales guidance, highlighted cost cuts, pipeline progress and noted uncertainties around CMV interim data, RSV market and combo vaccine filing.
- **2024 Q2:** Moderna reports Q2 2024 results with $184M product sales, lowers 2024 sales guidance to $3.0-3.5B due to weak EU demand, US competitive pressures, and potential revenue deferrals, while highlighting five Phase III vaccine successes and cost reductions. Cash $10.8B, targeting $9B year-end. RSV vaccin

## Theme arcs

- **Cost discipline** (improving): Moderna has consistently highlighted cost cuts and efficiency gains across calls
- **Regulatory approvals** (improving): The company has received approvals for mNEXSPIKE and mRESVIA, with pending approvals for flu and combo vaccines
- **Pipeline progress** (stable): Moderna's pipeline has seen a mix of progress and setbacks, with some programs advancing and others facing delays or discontinuation
- **Demand uncertainty** (deteriorating): Concerns around declining COVID vaccination rates and market competition have increased over time
- **Partnerships and collaborations** (new): Moderna has begun to explore partnerships for latent vaccines and other programs, marking a new direction for the company

## Fear persistence

- **Demand risk** [recurring]: Concerns around declining COVID vaccination rates and market competition have persisted across calls
- **Regulatory risk** [recurring]: Uncertainty around approvals for flu and combo vaccines has continued, with recent setbacks
- **Clinical risk** [recurring]: Concerns around efficacy and safety have been raised for various programs, including CMV and Norovirus vaccines
- **Market risk** [new]: The company has begun to face competition in the flu vaccine market, with established players and similar efficacy claims
- **Cash flow risk** [recurring]: Moderna's need to achieve cash breakeven by 2028 has been a persistent concern, with declining COVID revenue and uncertain pipeline progress

## Guidance path

2024 Q2:lowered → 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:raised → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/MRNA`